Information  X 
Enter a valid email address

Fusion Antibodies revenue rises as expected in first half

By BFN News | 01:29 PM | Tuesday 22 October, 2019

Antibody supplier Fusion Antibodies said it would post a rise in first-half revenue in line with its expectations for the full year. Revenue for the six months through September had risen to £1.7m, up from £0.7m on-year. The company had £1.3m cash at the end of September. 'We continued to see good revenue growth during this first six months and have had a strong improvement in the previous six months,' chief executive Paul Kerr said. 'We are continuing the rollout of RAMP, which has been well received, and are on track to deliver our Mammalian Antibody Library in 2020 as planned.' 'We remain confident of an encouraging second half and that the company will achieve significant revenue growth for the full year.' At 1:29pm: (LON:FAB) Fusion Antibodies Plc Ord 4p share price was +1p at 67.5p Story provided by

a d v e r t i s e m e n t